Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

Inclusion Criteria: Part 1 \& 2 * Healthy men or non-pregnant, non-lactating healthy women of non-childbearing potential, 18-60 years of age. * Must agree to use a highly effective method of contraception. * Body Mass Index (BMI) 18-33 kg/m2 as measured at screening. * Weight ≤100 kg at screening. * Normal lung function, defined as: FVC and FEV1 \> 80% predicted (based on age, height, race, sex, SaO2 \> 95% on room air. * Heart rate between 50 and 90 beats per minute (BPM). * Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination) and screening safety procedures. Inclusion Criteria: Part 3 * Diagnosis of IPF by American Thoracic Society/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Latin America Thoracic Society) 2011 criteria within five years prior to consent. * Men or non-pregnant, non-lactating women of non-childbearing potential. * Age ≥ 40 years. * Mild to moderate IPF as defined by predicted FVC ≥ 55% of normal and predicted DLCO \> 40% of normal at Screening. * Subjects receiving oral pirfenidone or nintedanib for treatment of IPF may participate if they have been on treatment with a stable, well-tolerated dose (as determined by the investigator), for at least 8 weeks prior to consent with no changes to therapy dose and schedule anticipated during the course of study participation. * Must be able to understand a written informed co…